Analysis of p53 mutations and the expression of p53 and p21WAF1/CIP1 protein in 15 cases of sebaceous carcinoma of the eyelid

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 1, 2010, Pages 7-11

  Kiyosaki, Kunihiro ^a   Nakada, Chisato ^a   Hijiya, Naoki ^a   Tsukamoto, Yoshiyuki ^a   Matsuura, Keiko ^a   Nakatsuka, Kazuo ^a   Daa, Tsutomu ^a   Yokoyama, Shigeo ^a   Imaizumi, Masamoto ^b   Moriyama, Masatsugu ^a  

^a OITA UNIVERSITY   (Japan)

^b Shinbeppu Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOSINE; PARAFFIN; PROTEIN P53; THYMINE; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EXON; EYELID CARCINOMA; FEMALE; GENETIC CODE; GENETIC CORRELATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MUTATIONAL ANALYSIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SEBACEOUS CARCINOMA; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; ENZYME IMMUNOASSAY; EYELID TUMOR; GENETICS; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYMERASE CHAIN REACTION; SEBACEOUS GLAND TUMOR;

ADENOCARCINOMA, SEBACEOUS; ADULT; AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA MUTATIONAL ANALYSIS; DOWN-REGULATION; EYELID NEOPLASMS; FEMALE; GENES, P53; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SEBACEOUS GLAND NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 75749108615     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4127     Document Type: Article

References (31)

1. Dasgupta T, Wilson LD, Yu JB. A retrospective review of 1349 cases of sebaceous carcinoma. Cancer. 2009;115:158-165.
2. Shields JA, Demirci H, Marr BP, Eagle RC Jr, Shields CL. Sebaceous carcinoma of the ocular region: a review. Survey Ophthalmol. 2005;50:103-122.
3. Yoon JS, Kim SH, Lee CS, Lew H, Lee SY. Clinicopathological analysis of periocular sebaceous gland carcinoma. Ophthalmologica. 2007;221:331-339.
4. Zurcher M, Hintschich CR, Garner A, Bunce C, Collin JR. Sebaceous carcinoma of the eyelid: a clinicopathological study. Br J Ophthalmol. 1998;82:1049-1055.
5. Boniuk M, Zimmerman LE. Sebaceous carcinoma of the eyelid, eyebrow, caruncle, and orbit. Trans Am Acad Ophthalmol Otolaryngol. 1968;72:619-642.
6. Doxanas MT, Green WR. Sebaceous gland carcinoma. Review of 40 cases. Arch Ophthalmol. 1984;102:245-249.
7. Shields JA, Demirci H, Marr BP, Eagle RC Jr, Shields CL. Sebaceous carcinoma of the eyelids: personal experience with 60 cases. Ophthalmology. 2004;111:2151-2157.
8. Becker K, Goldberg M, Helmbold P, Holbach LM, Loeffler KU, Ballhausen WG. Deletions of BRCA1/2 and p53 R248W gain-offunction mutation suggest impaired homologous recombination repair in fragile histidine triad-negative sebaceous gland carcinomas. Br J Dermatol. 2008;159:1282-1289.
9. Gonzalez-Fernandez F, Kaltreider SA, Patnaik BD, et al. Sebaceous carcinoma. Tumor progression through mutational inactivation of p53. Ophthalmology. 1998;105:497-506.
10. Borresen-Dale AL. TP53 and breast cancer. Hum Mutat. 2003;21: 292-300.
11. Toyooka S, Tsuda T, Gazdar AF. The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat. 2003;21:229-239.
12. Ziegler A, Leffell DJ, Kunala S, et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Nat Acad Sci U S A. 1993;90:4216-4220.
13. Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Nat Acad Sci U S A. 1991;88:10124-10128.
14. Rady P, Scinicariello F, Wagner RF Jr, Tyring SK. p53 mutations in basal cell carcinomas. Cancer Res. 1992;52:3804-3806.
15. Weihrauch M, Bader M, Lehnert G, Wittekind C, Tannapfel A, Wrbitzky R. Carcinogen-specific mutation pattern in the p53 tumour suppressor gene in UV radiation-induced basal cell carcinoma. Int Arch Occup Environ Health. 2002;75:272-276.
16. Matsuzoe D, Hideshima T, Ohshima K, Kawahara K, Shirakusa T, Kimura A. Discrimination of double primary lung cancer from intrapulmonary metastasis by p53 gene mutation. Br J Cancer. 1999;79:1549-1552.
17. Davidoff AM, Kerns BJ, Iglehart JD, Marks JR. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res. 1991;51:2605-2610.
18. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 1993;53:3369-3373.
19. Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A. TP53 and gastric carcinoma: a review. Hum Mutat. 2003;21:258-270.
20. Milner BJ, Allan LA, Eccles DM, et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res. 1993;53:2128-2132.
21. May P, May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene. 1999;18:7621-7636.
22. Daya-Grosjean L, Dumaz N, Sarasin A. The specificity of p53 mutation spectra in sunlight induced human cancers. J Photochem Photobiol. 1995;28:115-124.
23. Inga A, Scott G, Monti P, et al. Ultraviolet-light induced p53 mutational spectrum in yeast is indistinguishable from p53 mutations in human skin cancer. Carcinogenesis. 1998;19:741-746.
24. Kress S, Sutter C, Strickland PT, Mukhtar H, Schweizer J, Schwarz M. Carcinogen-specific mutational pattern in the p53 gene in ultraviolet B radiation-induced squamous cell carcinomas of mouse skin. Cancer Res. 1992;52:6400-6403.
25. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 2005;65:3980-3985.
26. Ito K, Sasano H, Matsunaga G, et al. Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J Pathol. 1997;183:318-324.
27. DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol. 1995;147:884-888.
28. Pasz-Walczak G, Kordek R, Faflik M. P21 (WAF1) expression in colorectal cancer: correlation with P53 and cyclin D1 expression, clinicopathological parameters and prognosis. Pathology, Res Pract. 2001;197:683-689.
29. Stein JP, Ginsberg DA, Grossfeld GD, et al. Effect of p21WAF1/ CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst. 1998;90:1072-1079.
30. Jiang M, Shao ZM, Wu J, et al. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int J Cancer. 1997;74:529-534.
31. Weinberg RA. The Biology of Cancer. London: Garland Science, Taylor and Francis Group; 2007:313.